Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours Β· Estimated delivery Aug 31 - Sep 5
Iran War Ceuta Migrants World Politics Entertainment HealthWatch MoneyWatch Crime Space Sports Brand Studio The Free Press Local News Atlanta Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Live CBS News 24/7 Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas 48 Hours 60 Minutes Shows 48 Hours 60 Minutes CBS Evening News CBS Mornings CBS Morning News CBS Reports CBS Saturday Morning The Daily Report The Dish Face the Nation Sunday Morning The Takeout Things That Matter The Uplift CBS News Investigates CBS News Confirmed Podcasts Newsletters Download Our App CBS News Team Executive Team Brand Studio Paramount+ Join Our Talent Community RSS Feeds Chicago | News Weather Sports Video Local News Indiana News Wisconsin News Investigators Politics Consumer HealthWatch Entertainment Business All Weather Chicago School Closings Flight Delays O'Hare Flight Delays Midway All Sports CBS Sports HQ Bears Bulls Blackhawks Cubs White Sox Fire Red Stars Sky Odds Station Info Meet Our Team Send a news tip Advertise Jobs & Internships Contests & Promotions Download App Memorials Watch CBS News FDA approves first oral GLP1 drug Foundayo The Food and Drug Administration has approved the first oral GLP-1 weight loss drug by Lilly, called Foundayo
Retatrutide at doses of 4 mg or higher significantly reduced fasting insulin (by 37% to 71%), HOMA2-IR (a measure of insulin resistance, reduced by 36% to 69%), and increased adiponectin (by 30% to 99%)
Peptide therapy has emerged as one of the most promising areas of longevity science because peptides can communicate directly with cells, helping restore functions that naturally decline with age
95% CI 0.58, 0.66
-Acts as a powerful antioxidant, reducing melanin production
